Healthcare cost by primary tumour, functioning status and treatment among patients with metastatic neuroendocrine tumours: The LyREMeNET study - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Neuroendocrinology Année : 2022
Fichier non déposé

Dates et versions

hal-04151010 , version 1 (04-07-2023)

Identifiants

Citer

Marine Perrier, Stéphanie Polazzi, Annie Lemelin, Violaine Fernandez, Stéphanie Labonne, et al.. Healthcare cost by primary tumour, functioning status and treatment among patients with metastatic neuroendocrine tumours: The LyREMeNET study. Journal of Neuroendocrinology, 2022, 34 (4), ⟨10.1111/jne.13092⟩. ⟨hal-04151010⟩
8 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More